175 related articles for article (PubMed ID: 1531951)
21. Sparteine oxidation polymorphism in Denmark.
Brøsen K; Otton SV; Gram LF
Acta Pharmacol Toxicol (Copenh); 1985 Nov; 57(5):357-60. PubMed ID: 4090995
[TBL] [Abstract][Full Text] [Related]
22. Genetically determined sparteine oxidation polymorphism in a Polish population.
Orzechowska-Juzwenko K; Pawlik J; Niewiński P; Milejski P; Dembowski J; Turek J; Goździk A; Swiebodzki L; Hora Z
Eur J Clin Pharmacol; 1994; 46(5):481-3. PubMed ID: 7957549
[TBL] [Abstract][Full Text] [Related]
23. Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine.
Sindrup SH; Brøsen K; Bjerring P; Arendt-Nielsen L; Larsen U; Angelo HR; Gram LF
Clin Pharmacol Ther; 1990 Dec; 48(6):686-93. PubMed ID: 2249379
[TBL] [Abstract][Full Text] [Related]
24. Extremely slow metabolism of amitriptyline but normal metabolism of imipramine and desipramine in an extensive metabolizer of sparteine, debrisoquine, and mephenytoin.
Brøsen K; Gram LF; Kragh-Sørensen P
Ther Drug Monit; 1991 Mar; 13(2):177-82. PubMed ID: 2053127
[TBL] [Abstract][Full Text] [Related]
25. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor.
Tulloch IF; Johnson AM
J Clin Psychiatry; 1992 Feb; 53 Suppl():7-12. PubMed ID: 1531829
[TBL] [Abstract][Full Text] [Related]
26. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan.
Kévorkian JP; Michel C; Hofmann U; Jacqz-Aigrain E; Kroemer HK; Peraldi MN; Eichelbaum M; Jaillon P; Funck-Brentano C
Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830
[TBL] [Abstract][Full Text] [Related]
27. Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population.
Griese EU; Asante-Poku S; Ofori-Adjei D; Mikus G; Eichelbaum M
Pharmacogenetics; 1999 Dec; 9(6):715-23. PubMed ID: 10634134
[TBL] [Abstract][Full Text] [Related]
28. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics of paroxetine in patients with cirrhosis.
Dalhoff K; Almdal TP; Bjerrum K; Keiding S; Mengel H; Lund J
Eur J Clin Pharmacol; 1991; 41(4):351-4. PubMed ID: 1839532
[TBL] [Abstract][Full Text] [Related]
30. Evidence for altered catalytic properties of the cytochrome P-450 involved in sparteine oxidation in poor metabolizers.
Osikowska-Evers B; Dayer P; Meyer UA; Robertz GM; Eichelbaum M
Clin Pharmacol Ther; 1987 Mar; 41(3):320-5. PubMed ID: 3816020
[TBL] [Abstract][Full Text] [Related]
31. Polymorphic CYP2D6 mediates O-demethylation of the opioid analgesic tramadol.
Paar WD; Poche S; Gerloff J; Dengler HJ
Eur J Clin Pharmacol; 1997; 53(3-4):235-9. PubMed ID: 9476037
[TBL] [Abstract][Full Text] [Related]
32. First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype.
Brøsen K; Gram LF
Clin Pharmacol Ther; 1988 Apr; 43(4):400-6. PubMed ID: 3356084
[TBL] [Abstract][Full Text] [Related]
33. Sparteine oxidation polymorphism: phenotyping by measurement of sparteine and its dehydrometabolites in plasma.
Paar WD; Schuhler H; Fimmers R; Dengler HJ
Eur J Clin Pharmacol; 1989; 36(6):555-60. PubMed ID: 2590312
[TBL] [Abstract][Full Text] [Related]
34. Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol.
Dayer P; Balant L; Kupfer A; Striberni R; Leemann T
Eur J Clin Pharmacol; 1985; 28(3):317-20. PubMed ID: 2861095
[TBL] [Abstract][Full Text] [Related]
35. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
Brøsen K; Skjelbo E; Flachs H
Br J Clin Pharmacol; 1993 Aug; 36(2):105-8. PubMed ID: 8398577
[TBL] [Abstract][Full Text] [Related]
36. Imipramine metabolism in relation to the sparteine oxidation polymorphism--a family study.
Madsen H; Hansen TS; Brøsen K
Pharmacogenetics; 1996 Dec; 6(6):513-9. PubMed ID: 9014200
[TBL] [Abstract][Full Text] [Related]
37. The genetic polymorphism of sparteine metabolism.
Eichelbaum M; Reetz KP; Schmidt EK; Zekorn C
Xenobiotica; 1986 May; 16(5):465-81. PubMed ID: 3739368
[TBL] [Abstract][Full Text] [Related]
38. Absence of polymorphism of sparteine oxidation in the South African Venda.
Sommers DK; Moncrieff J; Avenant JC
Hum Exp Toxicol; 1991 May; 10(3):175-8. PubMed ID: 1678945
[TBL] [Abstract][Full Text] [Related]
39. Genetically determined sparteine oxidation and sulfadimidine acetylation polymorphism in patients with non-occupational urinary bladder cancer.
Orzechowska-Juzwenko K; Niewiński P; Pawlik J; Milejski P; Dembowski J; Swiebodzki L; Lorenz J
Mater Med Pol; 1994; 26(4):145-8. PubMed ID: 7666680
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of the selective serotonin reuptake inhibitors.
DeVane CL
J Clin Psychiatry; 1992 Feb; 53 Suppl():13-20. PubMed ID: 1531816
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
